Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer-Reference-Cited by-同舟云学术

Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer

Published:2020-01 Issue: Volume:100 Page:104477
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Doumas Stergios,Foukas Periklis G.,Economopoulou Panagiota,Kotsantis Ioannis,Psyrri Amanda

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference72 articles.

1. Hyperprogression with immunotherapy: Is it real?;Popat;Cancer,2019

2. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma;Weber;N Engl J Med,2017

3. Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study;Gettinger;J Clin Oncol,2018

4. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations;Gong;JITC,2018

5. Advances in cancer immunotherapy 2019- latest trends;Kruger;J Exp Clin Can Res,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment;Cancer Letters;2024-08

2. Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma;Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology;2024-08

3. Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy;Cancer Treatment Reviews;2023-12

4. Emerging histological and serological biomarkers in oral squamous cell carcinoma: Applications in diagnosis, prognosis evaluation and personalized therapeutics (Review);Oncology Reports;2023-10-20

5. Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches;Cancer Treatment Reviews;2022-09